Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Core Viewpoint - The Invesco Biotechnology & Genome ETF (PBE) is designed to provide broad exposure to the Health Care ETFs category, focusing on biotechnology and genome sectors [1][5]. Fund Overview - PBE was launched on June 23, 2005, and is managed by Invesco, with assets totaling approximately $222.64 million, categorizing it as an average-sized ETF in the Health Care sector [1][5]. - The fund aims to match the performance of the Dynamic Biotechnology & Genome Intellidex Index, which evaluates companies based on various investment merit criteria [5][6]. Cost Structure - PBE has an annual operating expense ratio of 0.58%, which is competitive within its peer group, and a 12-month trailing dividend yield of 0.26% [7]. Sector Exposure and Holdings - The ETF has a significant allocation in the Healthcare sector, comprising about 99.8% of its portfolio [8]. - Illumina Inc (ILMN) represents approximately 5.81% of total assets, with the top 10 holdings accounting for about 47.68% of total assets under management [9]. Performance Metrics - As of July 22, 2025, PBE has experienced a year-to-date loss of approximately -3.56% and a one-year decline of about -6.19% [11]. - The fund has traded between $56.01 and $72.24 over the past 52 weeks, with a beta of 0.76 and a standard deviation of 21.29% over the trailing three-year period, indicating a higher risk profile [11]. Alternatives - Other ETFs in the biotechnology space include SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB), which have larger asset bases of $4.65 billion and $5.28 billion respectively, and lower expense ratios of 0.35% and 0.45% [12][13].